BioSpace News Archive

Business

4D Pharma Appoints John Beck as Chief Financial Officer and Member of the Management Team

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces the appointment of John Beck as Chief Financial Officer (CFO) and member of the Company’s management team

March 1, 2021
·
9 min read
Vial Adaptors For Reconstitution Drug Market: Affordability and Prevalence of Chronic Diseases Driving Demand

The global market for vial adaptors for reconstitution drugs has been experiencing a steady demand as these vial adaptors have come to be the safest solutions for quick transfer for drugs between vials.

March 1, 2021
·
4 min read
Business

Gyroscope Therapeutics Appoints Jessica Stitt as Chief Financial Officer

Gyroscope Therapeutics Limited, a clinical-stage gene therapy company focused on diseases of the eye, announced the appointment of Jessica Stitt as Chief Financial Officer, effective immediately.

March 1, 2021
·
2 min read
Evotec and Chinook Therapeutics Enter Into Strategic Collaboration to Discover and Develop Novel Precision Medicines for Chronic Kidney Diseases

Evotec SE and Chinook Therapeutics, Inc. announced a strategic collaboration focused on the discovery and development of novel precision medicine therapies for patients with chronic kidney diseases.

March 1, 2021
·
6 min read
Drug Development

BioInvent and Transgene has enrolled first patient in Phase I/IIa trial of novel oncolytic virus BT-001 in solid tumors

BioInvent International AB and Transgene announced that the first patient in a Phase I/IIa clinical trial of the novel dual mechanism-of-action oncolytic vaccinia virus BT-001 has been enrolled at Institut Bergonié.

March 1, 2021
·
9 min read
OKYO Pharma Limited (“OKYO” or the “Company”) - Issue of Equity

OKYO Pharma Limited announces that it has issued 250,000 ordinary shares of no par value, credited as fully paid, at a price of 4.5p per share on the exercise of 250,000 options.

March 1, 2021
·
1 min read
Bio NC

Verona Pharma to Present at H.C. Wainwright Global Life Sciences Virtual Conference

Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, will present a company overview at the H.C. Wainwright Global Life Sciences Conference.

March 1, 2021
·
2 min read
Merck KGaA, Darmstadt, Germany, Builds on Leadership in Head and Neck Cancer Through Worldwide Licensing Agreement with Debiopharm for Pivotal-Stage Xevinapant

Xevinapant is the first Inhibitor of Apoptosis Proteins antagonist with FDA Breakthrough Therapy Designation for previously untreated locally advanced squamous cell carcinoma of the head and neck, in combination with current standard of care

March 1, 2021
·
8 min read
Business

ERS Genomics Expands Team With Appointment of Jon Kratochvil as VP Business Development

Jon Kratochvil joins as Vice President for Business Development & Licensing for North America

March 1, 2021
·
2 min read
Biotech Bay

IDEAYA to Participate in Upcoming March 2021 Investor Relations Events

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation at the following upcoming investor relations events.

March 1, 2021
·
2 min read